Kairos Pharma, LTD.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| KAIROS PHARMA, LTD. | ||
| By: | /s/ John S. Yu | |
| John S. Yu | ||
| Chief Executive Officer and Chairman of the Board of Directors | ||
| Date: April 15, 2025 | Principal Executive Officer | |
|---|---|---|
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ John S. Yu | Chairman of the board of directors, | |
| John S. Yu | Chief Executive Officer | April 15, 2025 |
| (principal executive officer) | ||
| /s/ Doug Samuelson | Chief Financial Officer | |
| Doug Samuelson | (principal financial and accounting officer) | April 15, 2025 |
| /s/ Hyun W. Bae | Director | |
| Hyun W. Bae | April 15, 2025 | |
| /s/Hansoo Michael Keyoung | Director | |
| Hansoo Michael Keyoung | April 15, 2025 | |
| /s/ Rahul Singhvi | Director | |
| Rahul Singhvi | April 15, 2025 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.